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Abstract
The Human Immunodeficiency Virus type 1 (HIV-1) is classified into genetic groups, subtypes and
sub-subtypes which show a specific geographic distribution pattern. The HIV-1 epidemic in Italy, as
in most of the Western Countries, has traditionally affected the Intra-venous drug user (IDU) and
Homosexual (Homo) risk groups and has been sustained by the genetic B subtype. In the last years,
however, the HIV-1 transmission rate among heterosexuals has dramatically increased, becoming
the prevalent transmission route. In fact, while the traditional risk groups have high levels of
knowledge and avoid high-risk practices, the heterosexuals do not sufficiently perceive the risk of
HIV-1 infection. This misperception, linked to the growing number of immigrants from non-
Western Countries, where non-B clades and circulating recombinant forms (CRFs) are prevalent,
is progressively introducing HIV-1 variants of non-B subtype in the Italian epidemic. This is in
agreement with reports from other Western European Countries.
In this context, the Italian HIV-1 epidemic is still characterized by low subtype heterogeneity and
represents a paradigmatic example of the European situation. The continuous molecular evolution
of the B subtype HIV-1 isolates, characteristic of a long-lasting epidemic, together with the
introduction of new subtypes as well as recombinant forms may have significant implications for
diagnostic, treatment, and vaccine development. The study and monitoring of the genetic evolution
of the HIV-1 represent, therefore, an essential strategy for controlling the local as well as global
HIV-1 epidemic and for developing efficient preventive and therapeutic strategies.
Background
HIV-1 genetic subtypes
The Human Immunodeficiency Virus type 1 (HIV-1) iso-
lates are classified in three groups:group M (main), a
group O (outlier) as well as a group N (non-M/non-O)
[1-3]. The group M, responsible for the majority of infec-
tions in the HIV-1 worldwide epidemic, can be further
subdivided into 10 recognized phylogenetic subtypes or
clades (A – K, excluding E, which is actually a CRF), which
are approximately equidistant from one another (Fig. 1).
HIV-1 phylogenetic classifications are currently based
either on nucleotide sequences derived from multiple sub
genomic regions (gag, pol and env) of the same isolates or
on full-length genome sequence analysis. This approach
has revealed virus isolates in which phylogenetic relations
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with different subtypes switch along their genomes. These
inter-subtype recombinant forms are thought to have orig-
inated in individuals multiply infected with viruses of two
or more subtypes. This results in the generation of several
recombinants called "unique recombinant forms," or
URFs [4]. When an identical recombinant virus is identi-
fied in at least three epidemiologically unlinked people,
and is characterized by full-length genome sequencing, it
can be designated as circulating recombinant forms
(CRFs) [5-7]. The intra-genomic recombination appears
to be a very frequent event and the CRFs account for 18%
of incident infections in the global HIV-1 pandemic [8,9].
On a global scale, according to recent studies, the most
prevalent HIV-1 genetic forms are subtypes A, B, C and
CRF02_AG, with subtype C accounting for almost 50% of
all HIV-1 infections worldwide. In Europe, in particular,
subtype B is the circulating main genetic form, while sub-
type A viruses are predominant in east European countries
formerly constituting the Soviet Union, where they are
mainly transmitted among injecting drug users. Unlike all
the surrounding Countries, Romania is characterized by
an F subtype epidemic (Fig. 2).
HIV-1 epidemic in Italy
Injecting drug users (IDUs) have been the most affected
risk group during the first phase of the HIV epidemic in
Italy and the HIV-1 B subtype, in accordance with other
Western Countries, is the molecular form circulating
among IDUs [10]. However, the annual percentages of
AIDS cases reported in IDUs have gradually decreased to
32.3% in 2004 [11], in part as consequence of prevention
programs [12,13]. In parallel, the AIDS cases reported in
heterosexual individuals has continuously increased dur-
ing the epidemic, becoming in 2004 the most prevalent
risk factor for AIDS (40.4%) (Fig. 3) [10]. Similarly, in
2005 heterosexual contact accounts for over half (55%) of
HIV infections newly diagnosed in the EU, nearly half
(46%) of them were diagnosed in immigrants/migrants,
primarily from sub-Saharan Africa, and most of these
infections were acquired outside the EU (EuroHIV, 2006).
More than 10% of heterosexual individuals diagnosed
with AIDS in Italy are either immigrants from endemic
regions for HIV-1 (6.87%) or their Italian partners
(3.03%). This epidemiological evidence, not considering
all the HIV-1 infections derived also from traveling
abroad, suggests that at least 10% of the viruses transmit-
ted through heterosexual contacts could potentially
belong to non-B subtypes and CRFs. This has been
recently reported in other European Countries, with a
higher prevalence due to an older tradition of immigra-
tion waves and much tighter historical as well as eco-
nomic links with countries endemic for HIV-1 infection
[14-22]
Molecular evolution of the B-clade env sequences in the 
Italian epidemic
The biological relevance of genetic variations in the env
gene is due to the central role of the envelope protein in
the virus-host interaction. In particular, the V3 loop con-
tains epitopes for strain-restricted neutralizing antibodies,
it is a major determinant for viral tropism and co-receptor
usage, and its orientation partially masks the CD4 and
chemokine receptor binding sites [23-31].
The analysis performed including the B-subtype Italian
sequences [32-45] has shown a progressive increase of
nucleotide divergence in this region, increasing from
9.2% between isolates identified in the late 80's [46], to
17.51% between isolates identified in the early 2000's
[33,45]. This closely resembles the expected evolution of
a region under a strong immunological pressure during a
long-lasting epidemic [45,47].
Furthermore, a phylogenetic analysis performed on the
same C2-V3 env region (position 7001 to 7196 of HIV-
1HXB2) has shown the presence of an "Italian branch"
where the HIV-1 isolates are distributed into three major
Evolutionary relationships among non-recombinant HIV-1  strains Figure 1
Evolutionary relationships among non-recombinant 
HIV-1 strains. The phylogenetic tree shows the subtypes of 
the M (main) HIV-1 group. The phylogenetic analysis has 
been performed on near-full length sequences and is based 
on neighbor joining method. The reliability of the internal 
branches defining a subtype has been estimated from 1'000 
bootstrap replicates and the values are expressed as percent-
age.Retrovirology 2007, 4:34 http://www.retrovirology.com/content/4/1/34
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clusters, each of them including several sub-clusters (Fig.
4). The 143 sequences derived from the different studies,
selecting one sequence per patient deposited at the Los
Alamos Database, do not form independent clusters and/
or sub-clusters but are rather found inter-dispersed in the
sub-clusters. This is likely due to the fact that the majority
of the samples have been identified in Italy during over-
lapping periods in the early 90's. The distribution pattern
of the sequences within the sub-clusters is not signifi-
cantly associated to the risk factor for HIV-1 infection
(IVDU, homo- or heterosexuality), by nonparametric
Kruskal-Wallis test (p < 0,096). Moreover, the B1 cluster
includes the majority of sequences identified in a broad
time range, while the B3 cluster is prevalently based on
recent sequences identified in our study. Moreover, as
shown in Fig. 4, Italian B clade variants do not cluster with
sequences from known "B clade-derived" CRFs.
Rate of amino acid substitution and codon usage in the B-
clade V3 env sequences
The B clade C2-V3 env sequences identified during the
HIV-1 Italian epidemic have been subsequently analyzed
for the frequency of synonymous and non-synonymous
substitutions at each codon corresponding to the 35 aa
forming the V3 loop of the env gene. The analysis has
shown that very few codons (C1, R2, G17, G28, C35) are
characterized by no substitutions or synonymous substi-
tutions only, indicating the absolute conservation of
those specific amino acid residues. In contrast, the vast
majority of codons are characterized by a higher percent-
age of non-synonymous substitutions leading to amino
acid changes. Nevertheless, the only residues found with a
frequency < 80% at specific positions in the crown of the
V3 loop are S11, N13, T22 and E25, although these do not
seem to influence the binding of the gp120-CD4 complex
Geographical distribution of HIV-1 genetic forms circulating in Europe Figure 2
Geographical distribution of HIV-1 genetic forms circulating in Europe. Genetic forms predominant in the different 
European Countries are shown.Retrovirology 2007, 4:34 http://www.retrovirology.com/content/4/1/34
Page 4 of 9
(page number not for citation purposes)
to the CCR5 (Fig. 5). This is, in fact, mainly influenced by
substitutions in the stem of the loop [48].
Furthermore, amino acid substitutions in the V3 loop
show a significant uniform distribution in the HIV-1
sequences identified during the Italian epidemic, with the
exception of the T-to-A22 substitution (within the tip of
the loop) which is prevalent in the isolates identified in
the early 2000's.
The codon usage in the V3 region has been previously
associated with HIV-1 isolates identified in patients with
different risk factors. In particular, considering the second
glycine at the tip of the V3 loop, the GGG codon has been
associated with the homosexual risk group and the GGC
codon with the IDU risk group [43,49-51]. In Italian B
subtype sequences, the GGC codon is strongly associated
with intra-venous transmission (p < 0.015), while the
GGG codon is strongly associated with sexual (homo and
hetero) transmission of HIV-1 (p < 0.007) (Fig. 6). The
striking segregation of the GGC and GGG codons in the
virus variants transmitted through different routes could
be the consequence of different selections, including viral
tropism, genetic bottlenecks or a founder effect.
Non-B-clade env sequences in Italian epidemic
So far, during the entire HIV-1 epidemic in Italy, only
seven non-B clade env sequences have been described,
identified in heterosexual individuals (either immigrants
from sub-Saharan Africa or their Italian partners) [44,45];
[33,34]. In particular, a very recent near-full length
sequence analysis has shown that a HIV-1 isolate origi-
nally classified as A is actually close to the A3 sub-subtype
and does not cluster in any of the known subtypes. It
could potentially represents a novel sub-subtype, which
needs to be confirmed with the identification of at least
two additional related isolates in unlinked individuals
[52].
Molecular evolution of the B-clade protease sequences in 
Italian epidemic
The sequences relative to HIV-1 pol gene, and the protease
region in particular, have been extensively analyzed and
collected only from the year 2000, consequent to appear-
ance of viral isolates resistant to protease inhibitors (PI),
introduced as a component of anti-retroviral therapy
(ART) combinations. This effect has made obvious the
need to evaluate the resistant mutants to guide the choice
of drug combinations in heavily drug-treated HIV-1-
infected individuals as well as in recent treatment-naïve
seropositive individuals.
The nucleotide divergence of the protease region during
the HIV-1 epidemic in Italy has been evaluated including
all the B-subtype Italian sequences from the published
reports [53-64]. The analysis, unlike the analyses of the V3
env region, has shown a rather constant nucleotide diver-
gence in this region (6.83% – 7.68%) over the 2000–2006
period. These results confirm that, also in a long-lasting
Phylogenetic tree of HIV-1 env gene C2-V3 region from Ital- ian B-clade isolates Figure 4
Phylogenetic tree of HIV-1 env gene C2-V3 region 
from Italian B-clade isolates. The C2-V3 env region 
(position 7001 to 7196 of HIV-1HXB2) of 143 Italian HIV-1 
isolates, identified in the whole epidemic, has been aligned to 
reference sequences of all Group M subtypes, in order to 
generate the phylogenetic tree by the neighbor-joining 
method. The BIT indicates the "Italian branch" of the tree, 
which includes three major clusters B1 – B3. The reliability 
has been estimated from 1'000 bootstrap replicates. For edi-
torial convenience, only the percentage value for the Italian 
Branch has been shown. All other values are > 90%.
Distribution of AIDS cases in adult population in Italy Figure 3
Distribution of AIDS cases in adult population in 
Italy. The percentage of AIDS cases for each risk group, 
over the HIV-1 epidemic, is indicated by lines. Unknown, 
indicates the undefined risk for infection.Retrovirology 2007, 4:34 http://www.retrovirology.com/content/4/1/34
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epidemic, the pol genes (and the protease in particular) are
not driven to genetic change by immunologic pressure.
"Pharmacologic" pressure, instead, plays a significant role
in the evolution of the protease gene by inducing the con-
stant appearance and spread of mutant variants with
degrees of drug resistance [65]. In this perspective, the
synonymous and non-synonymous substitutions have
been evaluated for the protease  sequences described in
Italy, showing the presence of "hot spot" in the 99 pro-
tease codons, where the frequency of non-synonymous
substitutions has increased over the 2000–2006 period
with the presence of PI drugs in the ART combination. In
particular, sequences identified in ART-treated groups
[54-56] showed a > 2.5 fold-increase in the frequency of
non-synonymous substitutions at codons strongly associ-
ated with PI drug resistance, compared to sequences iden-
tified in a naïve group [62] (Fig. 7).
The phylogenetic analysis performed on the protease
region of the HIV-1 B-subtype Italian sequences showed,
as for the env region, an "Italian branch" including three
major clusters, each of them formed by several sub-clus-
ters (Fig. 8). Also for the protease gene, as for the env C2-
V3 region, sequences derived from the different studies do
not form independent clusters and/or sub-clusters but are
rather found inter-dispersed in the tree. Moreover, a distri-
bution pattern based on the risk factor for HIV-1 infection
(IVDU, homo- or heterosexuality) could not be assessed
due to undisclosed demographic information. It is to be
underscored that, as result of this phylogenetic analysis,
the sequence 3193_1620A (Accession # DQ348068),
deposited as B-subtype isolate [56], showed a strong phy-
logenetic link to the F1 subtype, suggesting that a revised
classification of this isolate in the Los Alamos DataBase is
appropriate.
Evolution pattern of the V3 loop Figure 5
Evolution pattern of the V3 loop. The percentage of synonymous and non-synonymous substitutions in each of the 35 
codons of the V3 Loop are indicated, together with the percentage of amino acid residue preservation at the specific position. 
The positions where the residue is found in < 80% of the sequences, are highlighted with light-gray boxes.Retrovirology 2007, 4:34 http://www.retrovirology.com/content/4/1/34
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The phylogenetic analyses, therefore, strongly suggest
that, as for the env region, the protease region of the pol
gene in HIV-1 B subtypes in Italy are derived from three
main molecular ancestors, which have continuously
evolved and spread among infected individuals during the
epidemic.
Non-B-clade protease sequences in Italian epidemic
The non-B clade protease sequences, described in Italy over
the 2000–2006 period [52,55,58,59,63,66,67], show
intra-clade nucleotide divergences ranging from 3,34%
(CRF01_AE) to 8,74% (F1), which are comparable to the
divergence values observed for the B-clade sequences.
Moreover, the phylogenetic analysis shows a limited evo-
lution for each subtype, suggesting a recent introduction
into Italy, although the limited number of isolates does
not allow significant strong correlations to be made (Fig.
9).
Gag sequences in Italian epidemic
Nucleotide sequence analysis of the gag gene has not been
a priority over the HIV-1 epidemic in Italy, and a very lim-
ited number of B as well as non-B clade sequences have
been described [44,45,52,68]. A comprehensive phyloge-
netic analysis confirms the original subtype classification
of the isolates and shows a distribution of the Italian B-
subtype in different sub-clusters, where the sequences
deriving from the different studies are found interspersed
(Fig. 10). The lack of "cross-epidemic" sequences, how-
ever, does not allow inferences on phylogenetic evolution
in gag.
Concluding remarks
The B clade remains predominant and is circulating
among all risk groups in the Italian epidemic, as observed
all across Western European Countries [69]. Nevertheless,
the structural genes of B subtype HIV-1 variants show a
Phylogenetic tree of HIV-1 protease gene from Italian B-clade  isolates Figure 8
Phylogenetic tree of HIV-1 protease gene from Italian 
B-clade isolates. The protease region of Italian B-clade HIV-
1 isolates, identified in the whole epidemic, has been aligned 
to reference sequences of all Group M subtypes, in order to 
generate the phylogenetic tree by the neighbor-joining 
method. The BIT indicates the "Italian branch" of the tree, 
which includes three major clusters B1 – B3. The reliability 
has been estimated from 1'000 bootstrap replicates. For edi-
torial convenience, only the percentage value for the Italian 
Branch has been shown. All other values are > 90%.
Distribution of codons in risk groups Figure 6
Distribution of codons in risk groups. The distribution 
of the four codons encoding the second glycine residue in 
the crown of the env gene V3 loop (GPGRAFYT) has been 
analyzed in HIV-1 sequences, identified in infected individuals 
with different risk practices.
Evolution pattern of the protease Figure 7
Evolution pattern of the protease. The percentage of 
non-synonymous substitutions in each of the protease 
codons were evaluated. The codons with the most significant 
difference between the sequences identified in naïve and 
ART-treated individuals are shown. The amino acid residues 
correspond to those found in the sequences identified in 
naïve individuals.Retrovirology 2007, 4:34 http://www.retrovirology.com/content/4/1/34
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continuous spectrum of genetic diversification, although
the currently circulating viruses appear to derive from a
few early "founders". The introduction and the spread of
non-B subtype HIV-1 isolates in the Italian epidemic, in
contrast, appear to be still limited. In particular, as
reported in other Western European countries, it is
strongly associated with heterosexual transmission
between local and immigrant/migrant partners. In this
regard, it has to be mentioned that the general strategy of
sequencing and performing phylogenetic analyses only
on the env  sub-genomic region, pursued in Italy and
worldwide for many years, could have resulted in missing
the identification of novel CRFs early in the Italian epi-
demic.
The Italian HIV-1 epidemic, therefore, represents a para-
digmatic example of the European situation, being still
characterized by low subtype heterogeneity. However, the
slow introduction and diffusion of non-B subtypes in the
population could progressively change the overall sce-
nario and drive the need of adapting the diagnostic and
treatment strategies currently used in European Countries.
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